Navigation Links
Aegera Initiates Phase 2 Clinical Trial Of AEG33773 - A Small Molecule Targeting Neuropathic Pain
Date:5/6/2009

MONTREAL, May 6 /PRNewswire/ - Aegera Therapeutics is pleased to announce the initiation of a Phase 2a, proof-of-concept, clinical trial for AEG33773, a novel, orally bio-available small molecule therapeutic addressing the under-served market of painful diabetic neuropathy.

The Phase 2a study, entitled A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of AEG33773 versus Placebo in Patients with Painful Diabetic Peripheral Neuropathy will evaluate the efficacy, safety and tolerability of three dose levels of AEG33773 in diabetic patients suffering from significant neuropathic pain. This study is underway in Canada and Aegera will soon initiate trial sites in the Unites States, where the IND has recently cleared the FDA regulatory review process, and also in Europe, where the regulatory documents are now under review by the appropriate regulatory authorities.

"We are very excited about this first Phase 2 study for AEG33773 which has demonstrated robust preclinical in vivo data in multiple models of neuropathic and inflammatory pain. Furthermore, AEG33773 could have the potential to treat chronic pain conditions well beyond painful diabetic neuropathy." commented Dr. Jacques Jolivet, M.D., Senior Vice President Clinical Development of Aegera.

"With the successful conclusion of the Phase 1 safety studies for AEG33773 and the initiation of the first Phase 2a trial in diabetic patients suffering from significant neuropathic pain, we are now focused on successfully completing this trial while identifying an appropriate development partner; this will ensure that our novel agent is developed rapidly and effectively for its first indication while exploring additional indications so as to expand this franchise on a global basis." added Dr. Michael J. Berendt, Aegera's President and CEO.

About Aegera Therapeutics Inc. (www.aegera.com'/>"/>

SOURCE AEGERA THERAPEUTICS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
2. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
3. Aegera Therapeutics welcomes two experienced executives to its board of directors
4. Aegera Therapeutics collaboration with Human Genome Sciences leads to the initiation of a Phase 1 clinical trial with lead IAP inhibitor HGS1029 and receipt of first milestone payment
5. Aegera Therapeutics phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting
6. Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
7. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
8. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
9. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
10. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
11. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... His Majesty Willem-Alexander, King of the Netherlands ... His Majesty Willem-Alexander, King of the Netherlands, has announced ... POET-DSM Advanced Biofuels’ Project LIBERTY cellulosic ethanol plant in ... will take part in the Grand Opening Ceremony to ... p.m. and tour the plant. POET-DSM is a joint ...
(Date:8/21/2014)... Aug. 21, 2014 Mathematic studies at the ... , and funded by the Jeffrey Epstein VI Foundation ... can be visually identified for elimination. These aggressive cells are ... which shows a topological map of what to look for ... research, for while tumor cells can be extracted from biopsy, ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 Pursuit ... selling optimization technology and services for Life Sciences ... “Grading Pharma’s Use of New Commercial Sales Models” ... & Analytics. , The article examines some innovative ... that are being tested in the pharmaceutical market. ...
(Date:8/21/2014)... On Wednesday of last week RENU 28, the world's first ... available for purchase in Australia and New Zealand, and the ... works is, if you think about the definition of aging, ... renewal within your body. If you think about the definition ... renewal. What RENU 28 does is it works with these ...
Breaking Biology Technology:His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 3Science Power Jeffrey Epstein and Harvard University Fund Project to Visually Stop Tumor Growth 2Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2RENU 28 Skin Care Now Available in Australia and New Zealand 2
... The Defense Advanced Research Projects Agency (DARPA) has awarded ... Science an $8.4 million grant for research on a ... electronic devices to keep their state even while powered ... The research has broad implications across ...
... Physicians at Thomas Jefferson University Hospital reported today on ... automated interpretation of coronary CT angiography (cCTA) by Rcadia,s ... disease (CAD) in the major coronary arteries as well ... at the Radiological Society of North America (RSNA) Annual ...
... Dec. 2, 2010 The Board of Directors of ... capital investments and customized company formation and business growth ... the approval of the nomination of Peter M. DeComo ... PLSG, effective immediately.  Mr. DeComo will replace Dr. D. ...
Cached Biology Technology:UCLA receives $8.4 million to lead research on ultra-low-power, non-volatile logic technologies 2Rcadia COR Analyzer System Safely Rules Out Coronary Artery Disease in Main Coronary Arteries and Branch Vessels 2The Pittsburgh Life Sciences Greenhouse Announces New Chairman of the Board 2
(Date:8/20/2014)... the University of Tbingen, Arizona State University, the Wellcome ... Health Institute (Swiss TPH) isolated Mycobacterium pinnipedii ... 1000 years old. The pathogen is a relative of ... causes disease in humans today. These researchers assume that ... coast. "The link to sea lions was unexpected" comments ...
(Date:8/20/2014)... the Oklahoma Medical Research Foundation a five-year, $14.5 million ... bacteria,s effects on humans. , For 10 years, ... studied the human immune response to anthrax bacteria as ... original funding came soon after anthrax-laced letters killed five ... attacks of Sept. 11, 2001. , The long-term ...
(Date:8/20/2014)... spiciness that is irresistible to some, but intolerable to ... their findings to develop a new drug candidate for ... inflammation or other problems. They reported their progress on ... in ACS, Journal of Medicinal Chemistry . , ... had pegged a compound called capsaicin as the active ...
Breaking Biology News(10 mins):$14.5 million grant awarded to continue anthrax studies 2
... ANN ARBOR, Mich.---The muscle-building abilities of hormones known as ... search and you,ll find not only scientific papers discussing the ... muscle tissue, but also scores of ads touting the purported ... spite of widespread interest in these potent molecules, key details ...
... 2010) -- The popular forage and turf grass called tall fescue ... area that,s estimated to be larger than Virginia and Maryland combined ... Indiana University suggests there is more to fescue than meets the ... in the Journal of Applied Ecology , show that a ...
... ( P. vivax ) malaria has been identified in ... those who do not express the Duffy blood group protein ... Western Reserve University School of Medicine, Pasteur Institute, and the ... 600 individuals from eight communities covering the main malaria transmission ...
Cached Biology News:U-M researchers solve a molecular mystery in muscle 2Study: Grass, fungus combination affects ecology 2Duffy-negative blood types no longer protected from P. Vivax malaria 2Duffy-negative blood types no longer protected from P. Vivax malaria 3
HistoScan AP Universal Goat Kit...
Interact with both DNA and RNA; fluorescence green (Em=525 nm) bound to DNA; and fluorescence red (Em=~650 nm) bound to RNA....
One bottle containing 30 ml of protein solution and 0.1% sodium azide....
...
Biology Products: